再生障碍性贫血分型及免疫抑制治疗选择  

Classification of aplastic anemia and choice of immunosuppressive therapy

作　　者：何广胜[1] HE Guang-sheng(Department of Hematology,the First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院,江苏省人民医院血液科,江苏南京210029

出　　处：《中国实用内科杂志》2021年第10期836-838,共3页Chinese Journal of Practical Internal Medicine

基　　金：卫生公益性行业科研专项经费项目(201202017);江苏省研究型医院学会贫血专项科研基金。

摘　　要：中性粒细胞绝对值为0的暴发型再生障碍性贫血(FAA)使用免疫抑制治疗(IST)效果欠佳,一线选择异基因造血干细胞移植(allo-HSCT)可能更好;输血依赖型非严重型再生障碍性贫血(TD-NSAA)易进展为严重型AA(SAA),IST较单用环孢菌素(CsA)治疗则更易见效;老年SAA需根据年龄、合并症等分层给予IST联合艾曲泊帕等促血小板生成素激动剂治疗。The efficacy of immunosuppressive treatment(IST)in fulminant aplastic anemia(SAA)with absolute neutrophil value of 0 is not good,and allogeneic hematopoietic stem cell transplantation(allo HSCT)might improve the outcomes of patients;Transfusion dependent non severe aplastic anemia(TD-NSAA)progress to severe AA(SAA)forwardly,and IST could works better than CsA alone for TD-NSAA;Elderly SAA should be treated with IST combined with hrombopoietin receptor agonist according to age and complications.

关 键 词：再生障碍性贫血 分型 免疫抑制治疗 

分 类 号：R551.3[医药卫生—血液循环系统疾病]